UPTRAVI® Is the Only Prostacyclin Pathway Therapy Indicated to Delay Disease Progression AND Reduce Risk of PAH-Related Hospitalization1,2
Primary Endpoint: Time to First PAH Disease Progression Event in GRIPHON1,2
Pivotal trial overall population (UPTRAVI® vs placebo): Time to first disease progression event1,3
Summary of primary endpoint events1
UPTRAVI® n=574 % (n)
Placebo n=582 % (n)
All primary endpoint events
27.0% (155)
41.6% (242)
FIRST EVENT WAS:
Hospitalization for PAH
13.6% (78)
18.7% (109)
Other disease progression (decrease in 6MWD plus worsening FC or need for other therapy)
6.6% (38)
17.2% (100)
Death
4.9% (28)
3.1% (18)
Parenteral prostanoid or chronic oxygen therapy
1.7% (10)
2.2% (13)
Need for lung transplantation or balloon atrial septostomy for worsening of PAH
0.2% (1)
0.3% (2)
This site is intended for U.S. healthcare professionals
You are now leaving UptraviHCP.com
Clicking CONTINUE below will take you to the selected site, the content for which Johnson & Johnson is not responsible and to which this Privacy Policy does not apply. We encourage you to read the Privacy Policy of every online service you visit.
Median time from PAH diagnosis in patients taking UPTRAVI®: 0.9 years
This article includes information that has not been approved by the Food and Drug Administration for UPTRAVI® (selexipag). Please see full Prescribing Information available on this website. Authors[s] of this article have received remuneration from Actelion Pharmaceuticals US, Inc., or its affiliates.
*Other=drugs and toxins (2%) and HIV (1%).
6MWD=6-minute walk distance; ERA=endothelin receptor antagonist; FC=Functional Class; GRIPHON=Prostacyclin (PGI2) Receptor Agonist In Pulmonary Arterial HypertensiON; HIV=human immunodeficiency virus; HPAH=heritable PAH; IPAH=idiopathic PAH; PAH-CHD=PAH associated with congenital heart disease with repaired shunts; PAH-CTD=PAH associated with connective tissue disease; PDE5i=phosphodiesterase type-5 inhibitor; WHO=World Health Organization.
1. UPTRAVI® (selexipag) full Prescribing Information. Actelion Pharmaceuticals US, Inc. 2. Sitbon O, Gomberg-Maitland M, Granton J, et al. Clinical trial design and new therapies for pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801908. doi:10.1183/13993003.01908-2018 3. Data on file. Actelion Pharmaceuticals US, Inc. Length and Population Size of PAH Pivotal Trials Confirmation. June 2024. 4. Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary hypertension. N Engl J Med. 2015;373:2522-2533 and suppl. 5. Data on file. Actelion Pharmaceuticals US, Inc. GRIPHON Baseline Characteristics Study Report.
